ULTRAGENYX PHARMACEUTICAL INC. Accounts Receivable, Allowance for Credit Loss
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Accounts Receivable, Allowance for Credit Loss of $72.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-05
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $72.00M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $61.00M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $57.00M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $55.28M.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2026-06-30 | $72.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $61.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $57.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $55.28M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $47.98M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $39.72M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $33.00M 10-K · filed 2026-02-18 | $33.34M 10-K · filed 2025-02-19 |
| 2024-09-30 | $32.93M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $27.97M 10-Q · filed 2024-08-02 | |
| 2023-12-31 | $17.03M 10-K · filed 2025-02-19 | $0.00 10-K · filed 2024-02-21 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-21 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-17 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-15 | |
| 2019-12-31 | $0.00 10-K · filed 2020-02-14 | |
| 2018-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |